Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

9431 ARTÍCULOS , VIENDO DEL 3736 AL 3750

Modifiable risk factors for cognitive impairment in Parkinson's disease: A systematic review and meta-analysis of prospective cohort studies

Guo Y, Xu W, Liu FT, Li JQ, Cao XP, Tan L, Wang J, Yu JT.

Mov Disord. 2019 Jun;34(6):876-883. doi: 10.1002/mds.27665. Epub 2019 Mar 14.

Th17 cells: a promising therapeutic target for Parkinson's disease?

Prots I, Winner B.

Expert Opin Ther Targets. 2019 Apr;23(4):309-314. doi: 10.1080/14728222.2019.1590336. Epub 2019 Mar 14.

Mind the gaps: What we don't know about cognitive impairment in essential tremor

Louis ED, Joyce JL, Cosentino S.

Parkinsonism Relat Disord. 2019 Jun;63:10-19. doi: 10.1016/j.parkreldis.2019.02.038. Epub 2019 Mar 1.

Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review

Dinda B, Dinda M, Kulsi G, Chakraborty A, Dinda S.

Eur J Med Chem. 2019 May 1;169:185-199. doi: 10.1016/j.ejmech.2019.03.009. Epub 2019 Mar 8.

Neurosurgical Approaches to Levodopa-Induced Dyskinesia

Martini ML, Mocco J, Panov F.

World Neurosurg. 2019 Jun;126:376-382. doi: 10.1016/j.wneu.2019.03.056. Epub 2019 Mar 14.

Deep brain stimulation for obsessive-compulsive disorder

Arya S, Filkowski MM, Nanda P, Sheth SA.

Bull Menninger Clin. 2019 Winter;83(1):84-96. doi: 10.1521/bumc.2019.83.1.84.

Extended-Release Amantadine for Levodopa-Induced Dyskinesia

Dashtipour K, Tafreshi AR, Pahwa R, Lyons KE.

Expert Rev Neurother. 2019 Apr;19(4):293-299. doi: 10.1080/14737175.2019.1592677. Epub 2019 Mar 20.

[Tremor: A Clinical Guide For The Non-Neurologist]

Carvalho V, Massano J.

Acta Med Port. 2019 Feb 28;32(2):149-157. doi: 10.20344/amp.11352. Epub 2019 Feb 28.

A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies

Espay AJ, Hausdorff JM, Sánchez-Ferro Á, Klucken J, Merola A, Bonato P, Paul SS, Horak FB, Vizcarra JA, Mestre TA, Reilmann R, Nieuwboer A, Dorsey ER, Rochester L, Bloem BR, Maetzler W; Movement Disorder Society Task Force on Technology.

Mov Disord. 2019 May;34(5):657-663. doi: 10.1002/mds.27671. Epub 2019 Mar 22.

Prodromal Parkinson's Disease: The Decade Past, the Decade to Come

Postuma RB, Berg D.

Mov Disord. 2019 May;34(5):665-675. doi: 10.1002/mds.27670. Epub 2019 Mar 28.

Spiny Projection Neuron Dynamics in Toxin and Transgenic Models of Parkinson's Disease

Du Y, Graves SM.

Front Neural Circuits. 2019 Mar 15;13:17. doi: 10.3389/fncir.2019.00017. eCollection 2019.

Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients

Klietz M, Greten S, Wegner F, Höglinger GU.

Drugs Aging. 2019 Jun;36(6):511-530. doi: 10.1007/s40266-019-00654-z.

Influencing factors when living with Parkinson's disease: A cross-sectional study

Ambrosio L, Portillo MC, Rodriguez-Blazquez C, Rojo JM, Martinez-Martin P; EC-PC Validation Group.

J Clin Nurs. 2019 Sep;28(17-18):3168-3176. doi: 10.1111/jocn.14868. Epub 2019 May 13.

Characterizing advanced Parkinson's disease: OBSERVE-PD observational study results of 2615 patients

Fasano A, Fung VSC, Lopiano L, Elibol B, Smolentseva IG, Seppi K, Takáts A, Onuk K, Parra JC, Bergmann L, Sail K, Jalundhwala Y, Pirtosek Z.

BMC Neurol. 2019 Apr 2;19(1):50. doi: 10.1186/s12883-019-1276-8.

Animals in the Brain

Mulroy E, Balint B, Adams ME, Campion T, Merello M, Bhatia KP.

Mov Disord Clin Pract. 2019 Feb 28;6(3):189-198. doi: 10.1002/mdc3.12734. eCollection 2019 Mar.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias